1228 — Canbridge Pharmaceuticals Balance Sheet
0.000.00%
- HK$60.33m
- HK$193.69m
- CNY85.10m
Annual balance sheet for Canbridge Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 361 | 746 | 463 | 137 | 10.5 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 25 | 27.9 | 19.1 | 31.2 | 16.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 391 | 812 | 505 | 210 | 45.4 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 15.6 | 29.5 | 145 | 109 | 3.64 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 586 | 893 | 702 | 395 | 117 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 108 | 186 | 278 | 328 | 483 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2,332 | 199 | 393 | 435 | 591 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -1,746 | 693 | 309 | -39.8 | -474 |
Total Liabilities & Shareholders' Equity | 586 | 893 | 702 | 395 | 117 |
Total Common Shares Outstanding |